The pandemic changed how we think about our health. Stuck at home with nowhere to be, millions of people started paying attention to their bodies in ways they never had before. Vitamin D supplements went mainstream. Sleep trackers appeared on wrists. Continuous glucose monitors—once exclusively for diabetics—began showing up on the arms of health-conscious optimizers.
That shift was just the beginning.
Beyond Data Collection: The "Reading" Becomes "Writing"
We've gotten good at monitoring. Apple Watch tracks your sleep. Oura Ring measures your recovery. CGM patches show you how your body responds to that burrito bowl. But here's what's changing: we're moving from passively reading our biology to actively writing to it.
Neuroscientist Andrew Huberman laid out this framework in a recent discussion. The "reading" phase used sensors—wearables, CGMs, sleep trackers—to gather data. The next phase involves actually modulating physiology: targeted neurotechnologies, localized cooling, pharmacological interventions that don't just report what's happening but change what's happening.
Think about what that means. Your watch doesn't just notice you're stressed—it could actively help you calm down. Your CGM doesn't just track glucose—it could guide insulin or peptide dosing in real time. We're building the feedback loops that were missing.
The CGM Revolution Isn't Just for Diabetics
Here's the part that surprises people: nearly one in seven Americans has now tried a GLP-1 drug. That's not a typo. GLP-1s—semaglutide, tirzepatide, and their successors—have exploded into mainstream use for weight management, metabolic health, and even preventive care.
But here's the tension: the pharmaceutical route is expensive and often scarce. Compounding pharmacies have emerged as a middle ground—providing peptide formulations at lower costs, though with legitimate questions about purity and sourcing. The black market for peptides exists too, and it's not worth the risk.
What Huberman emphasized: the compounders and gray market exist because demand far outstrips supply. When nearly 20% of Americans have tried these drugs, we're not talking about a niche anymore. We're talking about a fundamental shift in how people approach their own metabolism.
Sleep Is the New Frontier
If there's one high-impact target everyone agrees on, it's sleep. Sleep gates alertness. Alertness gates focus. And here's what most people don't realize: there are essentially no drugs that directly increase focus. The pharmacologically tractable lever is alertness—and sleep is how you pull it.
The next wave of sleep technology isn't about tracking better. It's about intervention. Eye masks that induce specific sleep states. Wearable light that wakes you at the optimal moment. Core cooling through your palms and feet to drop body temperature faster. These aren't science fiction—they're engineering problems that are close to solved.
What This Means For Startups
The opportunity map here is straightforward:
-
Continuous cortisol sensing is the missing link. We can track glucose continuously now, but cortisol—the stress hormone that gates everything—still requires blood draws. Real-time multi-biomarker sensors will close the loop on intervention timing.
-
Noninvasive stimulation via superficial nerves works. Vagus nerve stimulation through the ear. Cooling through the skin. These access points are proven and underexploited commercially.
-
The integration layer is wide open. Who combines wearables, CGMs, and intervention devices into coherent, automated health workflows? That's the next great consumer health product.
The Bigger Picture
We spent the last decade learning to measure ourselves. The next decade is about acting on that data. The companies that figure out how to move from passive monitoring to active modulation will own the biggest consumer health category since the smartphone.
The pandemic gave us permission to care about our health. Now we're building the tools to actually do something with that care.
This post was generated from TLDP's processed episode covering consumer health technology and the peptide revolution.